IPOGrid
0001734750
IPO filing research
Corvex, Inc.
Services-Computer Processing & Data Preparation · MOVE
follow-on
trading
filed
Nasdaq
S-1
Corvex, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-10. Current deal snapshot: exchange Nasdaq.
Filing Timeline
SEC EDGAR
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
First tracked pre-IPO filing for this issuer.
53,390,008 shares
Common Stock · Exchange Nasdaq · Ticker MOVE · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, with no proceeds to the issuer.
2026-07-10 · 0001213900-26-077253
RW
withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows EFFECT and ends the active registration process.
Movano Inc. has submitted a request to withdraw its previously filed Registration Statement on Form S-4, which was initially filed on December 22, 2025, and amended on February 5, 2026. The company cites internal business decisions as the reason for discontinuing the offering, confirming that the registration was never declared effective and no securities were issued or sold.
2026-03-19 · 0001213900-26-031583
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows EFFECT in the pre-IPO sequence.
2026-03-13 · 0001213900-26-027283
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
2026-03-04 · 0001213900-26-023243
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
The current filing marks the effectiveness of Movano Inc.'s S-1 registration statement for 545,456 shares of common stock, convertible from Series A Preferred Stock. The filing outlines the company's merger with Corvex, Inc., a reverse stock split, and ongoing Nasdaq compliance challenges. The registration enables selling stockholders to resell shares upon conversion, with no proceeds to Movano. The company remains an emerging growth company with reduced reporting requirements.
2026-02-17 · 9999999995-26-000608
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
545,456 shares
Common Stock · Exchange Nasdaq · Ticker MOVE · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, no issuer proceeds
Corvex, Inc. (Movano Inc.) filed an S-1/A registration statement for the resale of 545,456 shares of common stock by selling stockholders, convertible from Series A Preferred Stock. The filing highlights the pending merger with Corvex, Inc., Nasdaq compliance issues, and a reverse stock split. The company faces risks related to maintaining Nasdaq listing, liquidity, and merger execution.
2026-02-12 · 0001213900-26-015611
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
110,000,000 shares
Common Stock · Exchange Nasdaq · Ticker MOVE · Selling stockholders only · Use of proceeds Proceeds not specified · Underwriters Chardan Capital Markets LLC
Corvex, Inc. (Movano) is offering up to 110 million shares of common stock under a committed equity facility with Chardan Capital Markets LLC. The offering follows a merger agreement with Corvex, Inc., which includes a reverse stock split and ongoing compliance challenges with Nasdaq's stockholders equity requirements. The company faces risks related to delisting, merger execution, and reliance on Chardan for stock sales.
2026-02-09 · 0001213900-26-013723
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 424B5 filing.
Common Stock · Exchange Nasdaq · Ticker MOVE
2026-02-05 · 0001213900-26-012495
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
2026-01-23 · 0001213900-26-006833
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows S-1 in the pre-IPO sequence.
545,456 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, no proceeds to the company
Movano Inc. is registering 545,456 shares of common stock convertible from Series A Preferred Stock upon the merger with Corvex, Inc. The filing highlights a reverse stock split, Nasdaq compliance challenges, and the company's status as an emerging growth company. The merger structure, conversion mechanics, and ongoing listing risks are central to the offering.
2026-01-13 · 0001213900-26-004004
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows EFFECT in the pre-IPO sequence.
110,000,000 shares
Common Stock · Exchange Nasdaq · Ticker MOVE · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Chardan Capital Markets LLC
Movano Inc. is registering up to 110,000,000 shares of common stock under a committed equity facility with Chardan Capital Markets LLC, enabling periodic sales of shares subject to a purchase agreement. The offering follows a merger agreement with Corvex, Inc., a reverse stock split, and ongoing NASDAQ compliance challenges. The company faces risks related to delisting, merger execution, and uncertainty around share sales. Proceeds from the offering will not directly benefit Movano, but the facility could provide up to $1 billion in gross proceeds.
2025-12-22 · 0001213900-25-124017
S-4
filed
S-4
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
common · Exchange Nasdaq · Ticker CVEX · Use of proceeds To facilitate the merger and related transactions
2025-12-22 · 0001213900-25-124014
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
2025-12-22 · 0001213900-25-124007
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
2025-12-17 · 0001213900-25-122542
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B5 in the pre-IPO sequence.
2025-11-10 · 0001213900-25-107860
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Gross proceeds $8,293,515
Common Stock · Exchange Nasdaq · Ticker MOVE · Use of proceeds Working capital and general corporate purposes · Underwriters JonesTrading Institutional Services LLC
2025-04-09 · 0001213900-25-030358
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Common Stock, $0.0001 par value per share · Exchange Nasdaq · Ticker MOVE
2024-09-16 · 0001213900-24-079011
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $3,406,141 · Gross proceeds $3,406,141
Common · Exchange Nasdaq · Ticker MOVE · Use of proceeds general corporate purposes · Underwriters JonesTrading Institutional Services LLC
2024-05-29 · 0001213900-24-047509
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
The SEC has declared the company’s Form S-3 registration statement effective as of May 7, 2024 at 5:00 p.m. ET for file number 333-278885 (CIK 0001734750), covering the company (shown in the notice as Movano Inc.).
2024-05-07 · 9999999995-24-001403
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows CERT and confirms the priced prospectus.
Price $0.85 · 4,235,304 shares · Gross proceeds $3,600,008
Common · Exchange Nasdaq · Ticker MOVE · Over-allotment 635,296 · Use of proceeds working capital · Underwriters The Benchmark Company LLC
2023-11-16 · 0001213900-23-087974
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 8-A12B and confirms the priced prospectus.
Shares of Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters The Benchmark Company LLC
2023-11-14 · 0001213900-23-087042
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
Price $1.00 · 8,000,000 shares · Gross proceeds $8,000,000
Shares of Common Stock · Exchange Nasdaq · Ticker MOVE · Over-allotment 1,200,000 · Use of proceeds for general corporate purposes · Underwriters The Benchmark Company LLC
2023-06-14 · 0001213900-23-048662
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Underwriters The Benchmark Company LLC
2023-06-12 · 0001213900-23-048161
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
Price $1.40 · 4,644,000 shares · Gross proceeds $6,501,600
warrant for every two share · Exchange Nasdaq · Ticker MOVE · Over-allotment 696,600 · Warrants to purchase up to 2,322,000 shares of common stock at $1.57 per share, exercisable immediately, expiring 5 years from issuance · Underwriters Newbridge Securities Corporation
2023-01-31 · 0001213900-23-006225
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows DRS/A and confirms the priced prospectus.
warrant for every two share · Exchange Nasdaq · Ticker MOVE · Warrants to purchase common stock at $ per share, exercisable immediately, expiring five years from issuance · Use of proceeds Use of proceeds is for working capital · Underwriters Newbridge Securities Corporation
2023-01-26 · 0001213900-23-005326
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows DRS/A and confirms the priced prospectus.
Common Stock · Exchange Nasdaq · Ticker MOVE · Use of proceeds general corporate purposes · Underwriters B. Riley Securities, Inc.
2022-08-15 · 0001213900-22-048128
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
The SEC notice states that an S-3 registration statement (File No. 333-264116) for Movano Inc. (CIK 0001734750) became effective on May 25, 2022 at 4:30 P.M.
2022-05-25 · 9999999995-22-001590
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows DRS and confirms the priced prospectus.
Price $5.00 · 8,500,000 shares · Gross proceeds $42,500,000
Shares of Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Over-allotment 1,275,000 · Underwriter granted a warrant · Underwriters National Securities Corporation
2021-03-24 · 0001213900-21-017499
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 8-A12B and marks the registration effective.
Corvex, Inc. (referred to as Movano Inc. in the filing) filed an S-1 registration statement with the SEC, indicating preparation for an initial public offering (IPO). The filing confirms the effectiveness of the registration, allowing the company to offer its common stock on The Nasdaq Stock Market. The previous 8-A12B filing was related to registering securities under Section 12(b) of the Exchange Act, while the current S-1 signifies a transition to an IPO process.
2021-03-22 · 9999999995-21-001054
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2021-03-22 · 0001354457-21-000376
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
Movano Inc. filed a Form 8-A12B to register its common stock for listing on The Nasdaq Stock Market LLC. The filing incorporates by reference the description of capital stock from its earlier S-1/A registration statement, which detailed the company's initial public offering (IPO) of 7,200,000 shares at $5.00 per share. The 8-A12B does not include new financial details or material updates beyond referencing the existing S-1/A disclosure.
2021-03-19 · 0001213900-21-016571
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 7,200,000 shares · Gross proceeds $36,000,000
Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Over-allotment 1,080,000 · Underwriter Warrant to purchase shares up to 10% of the shares sold · Use of proceeds Proceeds to the company are $33,516,000 before expenses · Flags warrants · Underwriters National Securities Corporation
Corvex, Inc. (Movano Inc.) is conducting an initial public offering (IPO) of 7,200,000 shares of common stock at $5.00 per share, led by National Securities Corporation. The company develops a proprietary RF-based platform for non-invasive health monitoring, including a wearable device measuring glucose, blood pressure, and heart rate. Movano is an emerging growth company, leveraging reduced reporting requirements under the JOBS Act. Proceeds from the IPO will fund product development, commercialization, and operations.
2021-03-17 · 0001213900-21-016111
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Price $5.00 · 7,200,000 shares · Gross proceeds $36,000,000
Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Over-allotment 1,080,000 · Underwriter warrant to purchase up to 10% of shares sold, with 4,968,000 underlying shares · Use of proceeds Working capital and general corporate purposes · Flags warrants · Underwriters National Securities Corporation
Corvex, Inc. (formerly Movano, Inc.) filed an S-1/A amendment to its initial public offering (IPO) registration statement, finalizing details around the offering structure, registration fees, and underwriting terms. The filing confirms a $5.00 per share offering price for 7,200,000 common shares, with underwriting discounts and proceeds outlined. Key updates include finalized registration fee calculations, a 10% underwriter warrant, and revised dates for the prospectus and expected stock delivery. The company remains an emerging growth company with significant risks related to regulatory approvals, development timelines, and capital requirements.
2021-03-10 · 0001213900-21-014638
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Price $5.00 · 8,280,000 shares · Gross proceeds $41,400,000
Common Stock · Exchange Nasdaq Capital Market · Ticker MOVE · Underwriter warrant to purchase shares up to [●]% of the number sold · Flags emerging_growth_company · Underwriters National Securities Corporation
Corvex, Inc. is a health technology company developing a non-invasive, wearable device for continuous monitoring of glucose, blood pressure, and heart rate. The company is in the development phase, with no revenue generated to date. The S-1 filing outlines financial losses, reliance on equity financing, and plans to use IPO proceeds for research and development. It highlights competitive risks from larger firms and uncertainties around product commercialization and liquidity.
2021-02-02 · 0001213900-21-006218
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Corvex, Inc. is developing a non-invasive wearable device for continuous glucose, blood pressure, and heart rate monitoring. The company faces significant competition from established firms like DexCom, Abbott, and Medtronic, which have greater resources and market presence. Financially, Corvex has incurred substantial losses, with $8.5 million in operating losses for 2019 and $8.1 million in the first nine months of 2020. The company relies on external funding to sustain operations and advance product development, emphasizing the importance of the IPO for liquidity. The filing highlights risks related to competition, financial sustainability, and successful commercialization of its technology.
2021-01-11 · 0001213900-21-001487
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Corvex, Inc. provides pro forma financial calculations related to its upcoming IPO, detailing the impact of converting preferred stock and convertible notes into common shares. The filing outlines the expected increase in pro forma net tangible book value for existing shareholders and dilution for new investors. It includes sensitivity analyses for changes in offering price and share volume, as well as restrictions on share sales under Rule 144 and lock-up agreements. The underwriter, [●], acts as the lead managing underwriter, with an over-allotment option to purchase additional shares.
2020-08-31 · 0001213900-20-024631
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Corvex, Inc.'s DRS filing outlines the financial implications of its upcoming IPO, focusing on pro forma net tangible book value calculations. The document details how converting preferred stock and convertible notes into common shares would impact shareholder value, showing both the increase in value for existing shareholders and dilution for new investors. It also includes sensitivity analyses for different IPO price scenarios and share quantities, along with discussions about potential future share issuances and their dilutive effects. The filing emphasizes the underwriter's role in the offering and outlines lock-up agreements for insiders.
2020-06-30 · 0001213900-20-016335
Comparable Deals
20 comparable deals
TechnologyLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
QumulusAI, Inc.
QMLS
same SICrecent IPO
Liftoff Mobile, Inc.
LFTO
same SICrecent IPO
HawkEye 360, Inc.
HAWK
same SICrecent IPO
Csquare, Inc.
CSQR
same SIC grouprecent IPO
IQM Quantum Computers Oyj
IQMX
same SIC grouprecent IPO
Neutron Holdings, Inc.
LIME
same SIC grouprecent IPO
Bending Spoons S.p.A.
BSP
same SIC grouprecent IPO
Braiin Ltd
BRAI
same SICrecent IPO
Recent News
No recent news stored for this issuer.